ClearPath vs. Acclarent: The Directional Advantage

ClearPath vs. Acclarent: The Directional Advantage

If you searched “ClearPath vs. Acclarent,” you’re likely trying to do one of two things: 1) figure out how to breathe better if you have nasal blockage, or 2) decode which product or brand name refers to what.

Quick note: this is not a head-to-head product shootout. “ClearPath” (device context), “Acclarent” (brand), and “Clearpath” (IT company) live in different categories. This article clarifies those names and then explains where the idea of a “directional advantage” fits when you’re exploring deviated septum treatment and other minimally invasive options.

A common patient goal is simple: “What will actually help me breathe—without signing up for something bigger than I need?” Getting the categories straight is the first step.

Quick clarification: “Clearpath” can mean two different things

Clearpath Technologies (healthcare IT) ≠ ClearPath (a nasal device).

Clearpath Technologies is a healthcare IT company focused on speeding up digital access to medical records and imaging—a digital release workflow for hospitals and imaging centers. This is about information flow, not treatment. (Clearpath Technologies, n.d.; Konica Minolta Healthcare Americas, 2024)

In ENT conversations, “ClearPath” often refers to a nasal device and technique used in the context of directional balloon septoplasty or minimally invasive septal correction.

If you’re trying to understand whether you need a records/imaging solution or you’re evaluating a minimally invasive ENT approach to improve airflow, you’re in the right place.

What problem are you trying to solve? (Records vs. treatment)

If your issue is accessing records and scans quickly: you may be looking for a digital workflow that helps hospitals and imaging centers deliver records and imaging files (including DICOM) more reliably and with status tracking. That’s Clearpath Technologies’ domain—operational infrastructure, not a medical treatment. (Clearpath Technologies, n.d.) Example: If you’re switching ENTs or getting a second opinion, a digital release can eliminate “CD chasing,” reduce delays, and make it easier to share the actual images, not just the report.

If your issue is breathing or nasal blockage: if you have nasal obstruction, mouth-breathing, snoring related to blockage, or a suspected deviated septum, you’re likely comparing procedure approaches and trying to understand what “directional” means in practice. A helpful frame is: “Where is the blockage, and what’s the least disruptive way to create space?” Directional concepts aim to focus movement where it matters most for airway improvement. Background on causes and options: https://www.clearpathnasal.com/blog/deviated-septum-explained-symptoms-causes-and-modern-treatment-options

Clearpath Technologies’ role (healthcare IT): speed and visibility for records and imaging release

What it does: automates digital delivery of medical records and imaging for patient requests, legal requests, and care coordination; emphasizes integration (including PACS), request tracking, and HIPAA-aligned security. (Clearpath Technologies, n.d.)

Reported workflow impact: in a partner announcement with Konica Minolta’s Exa platform, the companies reported fulfillment 50% faster than manual or disc-based workflows, potential cost reductions up to 65%, and certain legal-request fulfillment in under five minutes. Vendor-reported; will vary by site and use case. (Konica Minolta Healthcare Americas, 2024)

Who benefits: patients needing imaging quickly for a consult or second opinion; clinics and hospitals aiming to eliminate delays and “CD chasing.”

Acclarent’s role (high level): ENT-focused technology ecosystem

When people compare “ClearPath vs. Acclarent,” they’re often mixing a device/technique concept (ClearPath in a nasal procedure context) with Acclarent, a brand associated with ENT procedural technology. Acclarent operates in the clinical/procedural layer and, following an acquisition completed in April 2024, sits within a larger medtech organization. (Integra LifeSciences, 2024)

Acclarent has also been associated with ENT navigation technology that uses AI concepts for intra-procedural guidance—3D anatomical mapping, real-time feedback, and path planning for certain sinus and skull-base procedures. (PR Newswire, 2021) This is not the same thing as directional correction of septal deviation, and AI navigation is not required for septoplasty.

What matters most for patients is the approach your clinician recommends for your anatomy and symptoms.

The “Directional Advantage” (where patients will actually feel the difference)

Plain-English view of “directional force”: think of straightening a slightly bent divider in a narrow hallway. A general push spreads force broadly; a directional approach aims force at the exact area that needs to move. In septal correction, the design intent is to focus correction where the deviation most compromises airflow, with the goal of minimizing unnecessary tissue disturbance. Comfort, bleeding, swelling, and recovery vary by anatomy, technique, and aftercare.

Deeper dive on force-directed dilation: https://www.clearpathnasal.com/blog/how-force-directed-dilation-changes-the-game

Important distinction from balloon sinuplasty

Balloon septoplasty (septal correction) is distinct from balloon sinuplasty (sinus opening for chronic sinus issues). They address different problems and use different techniques, even though both involve balloons.

Minimally invasive design intent (as described for the ClearPath device)

In a published report describing the ClearPath Nasal Balloon (CNB) approach, the technique is presented as using a force-directed balloon and shaped spatula to mobilize bony septal deviations, with an intent to reduce or avoid steps associated with traditional septoplasty such as broader flap elevation, packing, and prolonged anesthesia. (Dillard et al., 2026) CNB may be a less invasive alternative for selected candidates; suitability depends on anatomy and clinician judgment.

Early clinical findings (what’s been reported so far, and what it means)

Safety (retrospective series): in 107 consecutive cases, no reported major complications such as septal perforation, hematoma, synechiae, or conversion to a traditional flap-based surgery. Not proof of equivalence/superiority; no comparator arm. (Dillard et al., 2026)

CT alignment (subset): in 23 patients with pre/post CT, mean septal alignment reportedly improved by 45% at the site of maximal deviation and by 22% near the nasolacrimal duct (p = 0.005). Short-term, group-level change; outcomes vary. (Dillard et al., 2026)

Symptoms/quality of life (short-term): in 43 patients with one-month follow-up, SNOT-22 improved from 58.7 to 44.8 (23.8% reduction; p = 0.02), with improvements in congestion, pressure/headache, and sleep-related items. Uncontrolled, short-term, group-level data. (Dillard et al., 2026)

Balanced perspective on the evidence

The report is retrospective, includes small imaging and PRO subsets, and lacks a direct comparator (e.g., traditional septoplasty, other devices, or medical therapy). Larger prospective, comparative studies would help confirm findings and clarify which patients benefit most. For additional context on minimally invasive approaches vs traditional surgery: https://www.clearpathnasal.com/blog/clearpath-vs-traditional-septoplasty-recovery-safety-results

Candidate selection matters. Not all deviations are good matches for a balloon-based, force-directed approach—for example, some severe deformities, large spurs, caudal deviations, revision cases, or cases with significant concurrent turbinate or sinus disease may call for different techniques. Comfort and recovery vary with anatomy, procedural technique, and aftercare. Directional design intent does not guarantee an individual result.

In short, the directional concept is promising in carefully selected cases, but it is not a universal replacement for traditional approaches.

ClearPath vs. Acclarent: not direct competitors—different layers of care

ClearPath (device/technique): purpose—directional, minimally invasive intent for septal deviation in appropriate candidates; setting—procedure room/clinical; relevance—“directional advantage” is central; evidence—early, single-center retrospective safety, alignment, and short-term symptoms (no comparator).

Acclarent (brand): purpose—ENT procedural technologies, including image guidance/navigation; setting—procedure room/clinical; relevance—AI navigation relates to anatomical guidance, not directional septal force.

Clearpath Technologies (IT; with an “h”): purpose—digital delivery of records and imaging; setting—hospital/imaging center operations; relevance—“directional advantage” not applicable.

Think of it this way: one “Clearpath” improves information movement, while the ClearPath device discussion is about improving airflow. They can appear in the same journey—digital imaging transfer to your ENT, followed by a conversation about whether a minimally invasive septal approach fits your anatomy.

How to decide what you need (patient checklist)

If your goal is “I need my scans/records faster”: do you need the actual images (DICOM) for a second opinion or planning? Do you also need the radiology report? Ask your imaging center or hospital about digital release options; some use dedicated platforms to speed this up. (Clearpath Technologies, n.d.) Tip: confirm how your ENT wants files delivered to avoid delays. Bottom line: smoother information flow makes coordination easier.

If your goal is “I can’t breathe well through my nose”: get an evaluation so you’re not guessing. Blockage can arise from a deviated septum, turbinate enlargement, inflammation/allergies, nasal valve issues, or combinations. Questions to ask an ENT: do my symptoms fit a deviated septum and what else contributes? Am I a candidate for a minimally invasive septal approach, such as directional balloon septoplasty? If I’d like to avoid traditional septoplasty, what options fit my anatomy? What should I expect for recovery, discomfort, and follow-up? Office-based expectations: https://www.clearpathnasal.com/blog/what-to-expect-during-an-office-based-balloon-septoplasty Bottom line: the right approach matches your anatomy, symptoms, and goals.

FAQs

Is ClearPath the same as Acclarent? No. ClearPath (nasal device context) refers to a directional septal correction approach, while Acclarent is a brand associated with ENT procedural technologies. Separately, Clearpath Technologies (with an “h”) is an IT company focused on digital records and imaging workflows. (Clearpath Technologies, n.d.; Integra LifeSciences, 2024)

What does “directional” mean in balloon septoplasty? It generally means applying controlled, targeted force toward the area most responsible for airflow compromise, rather than relying on uniform expansion. In one retrospective series on CNB, the authors describe targeted mobilization with less broad tissue disruption than traditional approaches; real-world comfort and recovery vary. (Dillard et al., 2026)

Is AI surgical navigation used in sinus surgery? In some settings, image guidance and AI-supported navigation are used for complex sinus and skull-base procedures to support planning and intra-procedural orientation. That technology is separate from directional septal correction and is not required for septoplasty. (PR Newswire, 2021)

What outcomes matter most to patients? Common priorities include breathing comfort, congestion relief, sleep quality, facial pressure/headache related to blockage, and resuming normal activities. In one report on CNB, short-term SNOT-22 scores improved at one month, including congestion and sleep-related items; this was group-level, retrospective data without a comparator. (Dillard et al., 2026)

Conclusion: The real advantage is matching the tool to the goal

If your aim is to breathe better due to septal deviation, the “directional advantage” is most relevant when discussing targeted septal correction techniques in appropriately selected patients. For some anatomies, a minimally invasive, force-directed approach may be an option; for others, traditional septoplasty or alternative treatments may be more suitable. The best next step is an evaluation with an ENT who can confirm the cause of obstruction and review appropriate options. It’s reasonable to ask: “Am I a candidate for a minimally invasive, directional balloon septoplasty—or another approach that fits my anatomy and goals?”

References

Clearpath Technologies. (n.d.). Clearpath Technologies website. https://www.myclearpath.com/

Clearpath Technologies. (n.d.). For Patients. https://www.myclearpath.com/solutions/patients

Konica Minolta Healthcare Americas. (2024). Konica Minolta Healthcare Partners with Clearpath… https://finance.yahoo.com/news/konica-minolta-healthcare-partners-clearpath-120000289.html

Integra LifeSciences. (2024). Integra LifeSciences Completes Acquisition of Acclarent, Inc. https://investor.integralife.com/news-releases/news-release-details/integra-lifesciences-completes-acquisition-acclarent-inc

PR Newswire. (2021). Acclarent launches first ENT navigation technology powered by artificial intelligence. https://www.prnewswire.com/news-releases/acclarent-launches-first-ent-navigation-technology-powered-by-artificial-intelligence-301389359.html

Dillard J, et al. (2026). Rhinology Online, 9:18–23. doi:10.4193/RHINOL/25.018

This article is for educational purposes only and is not medical advice. Please consult a qualified healthcare provider for diagnosis and treatment.